Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21000344 | 0.84 | GAA (0.35) | GAANPC1RAB9A | |
| SCHEMBL22600072 | 0.81 | BTK (0.33) | DAO | |
| SCHEMBL15425489 | 0.78 | GAA (0.40) | GAANPC1RAB9ADAO | |
| SCHEMBL12311449 | 0.78 | GAA (0.40) | GAANPC1RAB9A | |
| SCHEMBL22230513 | 0.78 | GAA (0.40) | GAANPC1RAB9A | |
| SCHEMBL5501105 | 0.77 | DAO (0.38) | DAO | |
| SCHEMBL14357416 | 0.76 | GAA (0.39) | GAANPC1RAB9A | |
| SCHEMBL14447305 | 0.76 | GAA (0.39) | GAANPC1RAB9A | |
| SCHEMBL7904697 | 0.75 | P2RX7 (0.39) | GAANPC1RAB9A | |
| SCHEMBL9963861 | 0.74 | PIK3CD (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9427480-B2 | Duocarmycin ADCs for use in treatment of endometrial cancer | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2016-08-30 | — | — | US | disclosed |
| US-20160008487-A1 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | BYONDIS B.V. (NL) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008487-A1 | DUOCARMYCIN ADCS FOR USE IN TREATMENT OF ENDOMETRIAL CANCER | CD38, MKI67, ACR | GAA 2247/4885NPC1 3619/4885RAB9A 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.